Search

Displaying results 1741 - 1750 of 4207 in total
  1. Drug

    Hydrogenated soybean oil

    go.drugbank.com/drugs/DB11302
    Approved

    Linolenic acid and stearic acids are contained in hydrogenated soybean oil, but hydrogenation results in reduced unsaturation in linolenic acid.

  2. Drug

    Thiopental

    go.drugbank.com/drugs/DB00599
    ApprovedInvestigationalVet approvedWithdrawn

    It does not produce any excitation but has poor analgesic and muscle relaxant properties. Small doses have been shown to be anti-analgesic and lower the pain threshold.

  3. Drug

    Ramucirumab

    go.drugbank.com/drugs/DB05578
    ApprovedInvestigational

    By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stimulated receptor phosphorylation and downstream ligand-induced proliferation,

  4. Drug

    Piretanide

    go.drugbank.com/drugs/DB02925
    Approved

    Piretanide (INN, trade names Arelix, Eurelix, Tauliz) has been synthesized in 1973 at Hoechst AG (Germany) as a loop diuretic compound by using a then-new method for introducing cyclic amine residues in

  5. Drug

    Tannic acid

    go.drugbank.com/drugs/DB09372
    ApprovedInvestigational

    Tannic acid is also taken by mouth and applied directly for bleeding, chronic diarrhea, dysentery, bloody urine, painful joints, persistent coughs, and cancer. … Tannic acid is found in the nutgalls formed by insects on twigs of certain oak trees (Quercus infectoria and other Quercus species). It is removed and used as medicine.

  6. Drug

    Ambroxol

    go.drugbank.com/drugs/DB06742
    ApprovedInvestigational

    It stimulates synthesis and release of surfactant by type II pneumocytes. … Surfactants acts as an anti-glue factor by reducing the adhesion of mucus to the bronchial wall, in improving its transport and in providing protection against infection and irritating agents.

  7. Drug

    Cabazitaxel

    go.drugbank.com/drugs/DB06772
    ApprovedInvestigational

    It was first approved by the FDA on June 17, 2010.[A260421] It was also approved by the EMA on March 17, 2011 [L47381] and Health Canada on December 17, 2019.[L47376]

  8. Drug

    Lutetium Lu-177 vipivotide tetraxetan

    go.drugbank.com/drugs/DB16778
    ApprovedInvestigational

    [L43787] In December 2022, lutetium Lu-177 vipivotide tetraxetan was approved by the EMA.[L43787,L45533] … [L41280] Lutetium Lu-177 vipivotide tetraxetan was first approved by the FDA on March 23, 2022 as a treatment for prostate-specific membrane antigen–positive metastatic castration-resistant prostate

  9. Drug

    CCX915

    go.drugbank.com/drugs/DB05159
    Experimental

    CCX915 is developed by ChemoCentryx which targets the chemokine receptor CCR2 and is in phase 1 of clinical trial for the treatment of Multiple Sclerosis and Neurologic Disorders.

  10. Drug

    Leniolisib

    go.drugbank.com/drugs/DB16217
    ApprovedInvestigational

    [L45758] APDS is a primary immunodeficiency caused by mutations in genes encoding the PI3Kδ, thereby increasing the activity of PI3Kδ, causing immune dysfunction, and elevating susceptibility to infections